AstraZeneca Opens New R&D Center in Beijing, Expanding China Investment
Table of Contents
Beijing, China – October 27, 2023 – AstraZeneca, the global biopharmaceutical company, has inaugurated a significant new research and development (R&D) center in Beijing, marking a substantial expansion of its presence in china. This facility, the companyS sixth globally and second in China, is part of a broader $2.5 billion investment plan announced earlier this year.
The new R&D center, officially opened on october 25, 2023, is strategically located within the Beijing International Pharmaceutical Innovation Park (BioPark). This location provides proximity to leading biotechnology companies, research hospitals, and the National Medical Products Governance (NMPA), fostering collaboration and accelerating innovation.
Expanding R&D Capabilities in china
The Beijing center is equipped with state-of-the-art facilities, including advanced artificial intelligence (AI) and data science capabilities, designed to accelerate early-stage research and clinical development. AstraZeneca currently employs approximately 1,700 people in Beijing, and the new center is expected to bolster the company’s R&D efforts within the country and reinforce Beijing’s position as a global life sciences hub.
“The center will leverage Beijing’s world-leading scientific ecosystem and AI advantages to hasten the development of new-generation innovative drugs, offering new treatment possibilities for patients in China and globally,” stated AstraZeneca Chief Executive Pascal soriot at the Innovation Ecosystem Forum in Beijing on October 25th. https://www.astrazeneca.com/media/press-releases/2023/astrazeneca-opens-new-rd-centre-in-beijing-to-accelerate-innovation-in-china.html
collaboration and Synergy with Existing Hubs
AstraZeneca plans to foster partnerships with local hospitals, universities, and biotech firms to drive innovation. The Beijing center will also work in close coordination with AstraZeneca’s existing R&D hub in Shanghai, which was inaugurated in October 2021. The Shanghai center focuses on advancing the research, development, and clinical trials of both domestically-developed and internationally-sourced medicines. https://www.astrazeneca.com/content/dam/az/sustainability/2022/Annual_Report/AZ_AR22_China_case_study.pdf
AstraZeneca’s Long-Term Commitment to China
AstraZeneca first entered the Chinese market in 1993 and views the country as a key strategic market. To date, the company has introduced over 40 innovative medicines to China. Beyond its R&D centers in Beijing and Shanghai, AstraZeneca operates manufacturing facilities in Wuxi, Taizhou, and Qingdao, supplying medicines to more then 70 markets worldwide. https://www.astrazeneca.com/china.html
Key Takeaways:
* AstraZeneca has opened a new $2.5 billion R&D center in Beijing.
* The center will focus on leveraging AI and data science to accelerate drug revelation.
* This investment underscores AstraZeneca’s commitment to the Chinese market and its growing importance in global pharmaceutical innovation.
* The Beijing center will collaborate with local institutions and AstraZeneca’s Shanghai R&D hub.
Looking Ahead:
AstraZeneca’s continued investment in China signals a long-term commitment to addressing the country’s evolving healthcare needs and contributing to global medical advancements. the company’s expanded R&D footprint is poised to accelerate the development of innovative medicines and improve patient outcomes both within china and around the world.
date of Publication: October 27, 2023